LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies

 LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies

LogicBio Signs an Option Agreement with Canbridge to Develop Gene Editing Therapies

Shots:

  • LogicBio to receive $10M up front with ~$581M as option payment and milestones along with royalties. Canbridge to get an exclusive option to license LB-001 in Greater China and two additional undisclosed gene therapy programs.
  • The agreement also grants CANbridge a WW license for AAV sL65 which is the first capsid produced from LogicBio’s sAAVy platform, and development support on gene therapy candidates for Fabry and Pompe disease + two optional indications
  • Canbridge will responsible for the development, regulatory, commercial, and manufacturing activities in the licensed territory upon exercise of an option

Click here to­ read full press release/ article | Ref: PRNewswire | Image: LogicBio

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post